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Abstract
Background: Formation of haemorrhagic neovessels in the intima of developing atherosclerotic
plaques is thought to significantly contribute to plaque instability resulting in thrombosis. C-reactive
protein (CRP) is an acute phase reactant whose expression in the vascular wall, in particular, in
reactive plaque regions, and circulating levels increase in patients at high risk of cardiovascular
events. Although CRP is known to induce a pro-inflammatory phenotype in endothelial cells (EC)
a direct role on modulation of angiogenesis has not been established.
Results: Here, we show that CRP is a powerful inducer of angiogenesis in bovine aortic EC (BAEC)
and human coronary artery EC (HCAEC). CRP, at concentrations corresponding to moderate/high
risk (1–5 μg/ml), induced a significant increase in proliferation, migration and tube-like structure
formation in vitro and stimulated blood vessel formation in the chick chorioallantoic membrane
assay (CAM). CRP treated with detoxi-gel columns retained such effects. Western blotting showed
that CRP increased activation of early response kinase-1/2 (ERK1/2), a key protein involved in EC
mitogenesis. Furthermore, using TaqMan Low-density Arrays we identified key pro-angiogenic
genes induced by CRP among them were vascular endothelial cell growth factor receptor-2
(VEGFR2/KDR), platelet-derived growth factor (PDGF-BB), notch family transcription factors
(Notch1 and Notch3), cysteine-rich angiogenic inducer 61 (CYR61/CCN1) and inhibitor of DNA
binding/differentiation-1 (ID1).
Conclusion: This data suggests a role for CRP in direct stimulation of angiogenesis and therefore
may be a mediator of neovessel formation in the intima of vulnerable plaques.
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Atherosclerosis is the underlying cause of ischemic cardi-
ovascular and cerebrovascular diseases [1-3]. Unstable
carotid atherosclerotic plaques can undergo thrombotic
complications and trigger acute clinical events [4-6]. In
atherosclerotic plaques angiogenesis allows the formation
of new microvessels to maintain oxygen and nutrient sup-
ply for vascular cells. Such processes are potenciated by
different molecules secreted by vascular and inflamma-
tory cells [5]. Neovessel growth occurs in active regions of
atherosclerotic lesions undergoing remodelling. Our pre-
vious studies have demonstrated specific molecular dereg-
ulation occurring in these regions, consistent with the
promotion of angiogenesis. The new vessels of atheroscle-
rotic lesions may be a focus of instability, since they facil-
itate the infiltration of inflammatory cells and due to their
tendency to leak, may produce haemorrhagic complica-
tions [5,7-9]. In a previous study using protein microar-
rays, we have identified regulation of potentially
proangiogenic proteins associated with haemorrhagic ves-
sels in unstable plaques among them c-Jun N-terminal
kinase (JNK) and c-src [10].
The role of CRP modulating of angiogenesis in developing
atherosclerotic lesions has not been investigated. CRP is
an acute-phase reactant expressed during active inflam-
mation [11-16]. Inflammation, the key regulator of CRP
synthesis, plays an important role in atherothrombotic
cardiovascular and cerebrovascular disease [2]. CRP con-
sists of five identical non-covalently associated and nong-
lycosylated 23-kDa subunits arranged symmetrically
around a central pore and it is synthesized mainly in the
liver under the control of interleukin-6 (IL-6) [17,18],
although it is also found in other tissues including carotid
atherosclerotic plaques [5,19,20]. CRP represents one of
the strongest independent predictors of symptomatic
atherothrombosis and vascular death [21-23] and predicts
progression of atherosclerosis [24]. In response to acute-
phase stimuli, plasma CRP concentration can increase
rapidly and dramatically up to 100-fold [25]. CRP levels
are increased in patients at moderate- (1 to 3 μg/ml) and
high-risk (> 3 μg/ml) of future cardiovascular events [21].
Although, originally CRP was suggested to be purely a
biomarker, recent studies have pointed that it may in fact
be a direct mediator of atherosclerosis [26]. Indeed, CRP
elicits multiple effects on the vascular wall favouring a
proatherosclerotic phenotype. These include attraction of
monocytes, mediation of low-density lipoproteins (LDL)
uptake by macrophages [27,28] reduction in nitric oxide
(NO) release of human EC [29,30], up-regulation of
adhesion molecules [31], stimulation of vascular smooth
muscle cell (VSMC) proliferation and migration [32],
increasing matrix metalloproteinase (MMP) expression in
EC and macrophages [33-35], activating the complement
system [36] and inducing plasminogen activator inhibi-
tor-1 (PAI-1) expression and activity in human aortic EC
[37]. With regard to CRP effects on EC, published studies
are somewhat controversial. CRP has been shown to pro-
mote production of the pro-angiogenic molecules such as
endothelin-1 (ET-1) and IL-6 in human saphenous vein
EC [31], and activate NF-κB signalling through the CD32
receptor [38]. In contrast, other studies suggested that EC
activation by CRP was due to contamination of the com-
mercially obtained protein with lipopolysaccharide (LPS)
and/or sodium azide [39,40].
As we have previously demonstrated increased CRP
expression in unstable highly vascularized regions of
carotid lesions, we decided to investigate the angiogenic
properties of this molecule. Here we show that native CRP
and not potentially contaminating LPS or azide is strongly
angiogenic both in vitro and in vivo, and activates the
expression of some important pro-angiogenic genes in
endothelial cells.
Results
Chemotaxis was induced by CRP in both HCAEC and 
BAEC
Both native and CRPdt significantly increased chemotaxis
of HCAEC with a maximum effect at 5 μg/ml following
CRPdt treatment (approximately 290% over controls; p <
0.01) (Figure 1A). CRP also induced a significant increase
in chemotaxis of BAEC at similar concentrations with a
maximum response at 5 μg/ml CRP (approximately 175%
over controls; p < 0.001, data not shown). FGF-2 (25 ng/
ml) was used as a positive control. LPS alone (1 ng/ml)
had no effect on cell migration. Blocking experiments
were performed with the anti-CRP antibody (1:5) to
ensure that the effect was due to the CRP protein itself.
The increase in chemotaxis induced by CRPdt was signifi-
cantly reduced following the pre-incubation with anti-
body. (Figure 1B)
CRP stimulated BAEC but not HCAEC proliferation
A significant increase in BAEC proliferation (approxi-
mately 40% over controls; p < 0.05) was seen 72 h after
treatment with 1 μg/ml native CRP (Figure 2). Treatment
of CRP with detoxi-gel columns (CRPdt) did not amelio-
rate proliferation, and in fact, a further increase was
shown (approximately 80% over controls; p < 0.01). At 5
μg/ml CRPdt also produced a significant effect. Endotoxin
(LPS 1 ng/ml) alone had no effect on BAEC proliferation.
CRP did not affect proliferation of HCAEC at any of the
concentrations tested (data not shown).
CRP induced tube-like structure formation in HCAEC and 
BAEC
CRP induced the formation of tube-like structures in
growth factor depleted matrigel in both HCAEC andPage 2 of 14
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by approximately 4 fold at 1–5 μg/ml (p < 0.01). (Figure
3). CRPdt and non-detoxified CRP produced a similar
effect. LPS (1 ng/ml) had no effect. Similar results were
obtained in BAEC, in this case the maximal effect was
observed at 1 and 5 μg/ml with CRPdt (approximately a
3-fold increase; p ≤ 0.01) which are lower than showed by
FGF-2 treated cells (positive control)(Figure 4 and Figure
5A). Tube formation was significantly inhibited in cells
pre-incubated with anti-CRP antibody, p < 0.01 (Figure
5B).
CRP stimulated blood vessel formation in the CAM assay
CRPdt (5 μg/ml) was chosen following our in vitro studies
for analysis of angiogenesis in the CAM assay. CRPdt
induced blood vessel formation after 7 days treatment
compared with the control, as evidenced by the spoke
wheel pattern formation (mean value of 2, from 15 repli-
cates, p < 0.001; Figure 6A, control and B, CRPdt). FGF-2
(25 ng/ml) was used as a positive control and gave a
strong positive response (Figure 6C). Membranes treated
with the equivalent concentration of sodium azide or with
LPS (1 ng/ml) alone showed no significant response (data
not shown).
CRP stimulated angiogenic sprouting of aortic tissue
We used a rat aortic ring assay to examine the effects of
CRP on angiogenesis. We showed that CRP stimulated
microvessel sprouting from the cultured aortic rings (area
occupied by sprout microvessels of aortic rings; control,
2,3 ± 0,3; CRP (1 μg/ml) 10,5 ± 0,8; FGF-2 (25 ng/ml),
11,1 ± 0,03; p < 0.01). (Figure 7)
A, CRP induced a significant increase in chemotaxis in HCAECFigure 1
A, CRP induced a significant increase in chemotaxis in HCAEC. Cell migration was measured using a modified Boyden chamber 
as described in Methods. The effect of 1–5 μg/ml CRP (non-detoxified and detoxified CRP [CRPdt]) on HCAEC chemotaxis is 
shown. Endotoxin alone (LPS; 1 ng/ml) had no effect. B, Migration experiments were performed at least twice in triplicate 
wells. B, rhCRP (1 μg/ml) induced migration as compared with control and rhCRP (1 μg/ml)+antiCRP Ab(1:5). * and ** indicate 
a statistically significant difference compared with the control cells (p > 0.05 and 0.001 respectively).
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matrices
We investigated the effects of CRPdt on invasion/migra-
tion using HCAECs in 3D-Matrigel™ matrices. Unstimu-
lated HCAEC (control) showed a low level of network
formation (Figure 8). However, when an HCAEC network
was preformed in Matrigel™ in the presence of FGF-2 (25
ng/ml), CRPdt (1 ug/ml) stimulated an invasion into a
second layer of 3D-Matrigel™ matrices (Figure 8, arrows).
CRP increased the phosphorylation of ERK1/2
Phosphorylation of ERK1/2 is a key event associated with
mitogenesis in vascular EC, and we have previously
shown that its inhibition in BAEC is sufficient to prevent
growth factor stimulation of angiogenesis [41]. Semi-con-
fluent ECs (BAEC and HCAEC) cultured in SPM for 48 h
were treated with CRP/CRPdt (1 or 5 μg/ml) or FGF-2 (25
ng/ml; positive control), and incubated for 8 min (opti-
mum time for phosphorylation as determined in our pre-
vious published studies) [41]. Both CRP and CRPdt
notably increased phosphorylation of ERK1/2 in HCAEC
(Figure 9) and BAEC (data not shown). Neither purified
endotoxin nor sodium azide induced ERK1/2 activation
(data not shown).
CRP stimulated gene expression of multiple angiogenic 
markers
HCAEC were treated for various times with CRP (see
methods). Table 1 shows results obtained by quantitative
TaqMan low-density array analysis corresponding to 6
genes involved in angiogenesis that increased more than
1.5 fold in CRP treated HCAEC compared to the control
azide-only cells (1.0) in two separate experiments. These
genes were two members of the Notch family (Notch1
and Notch3), VEGF receptor-2 (KDR), the main VEGF
receptor, the mitogen platelet derived growth factor-beta
(PDGFβ), cysteine-rich 61 (CYR61), which stimulates
angiogenesis following integrin binding, and inhibitor of
DNA binding 1 (ID1). No studied angiogenic genes were
down-regulated compared with control cells.
Discussion
Several studies have suggested CRP as biomarker for cardi-
ovascular and cerebrovascular diseases [13,14]; however,
this protein also seems to be a mediator of atherosclerosis
[26,27]. Angiogenesis is a recognised mechanism
involved in the development of complicated atheroscle-
rotic plaques and previous studies have provided contro-
versial data regarding the possible angiogenic or anti-
angiogenic effect of CRP. In this work, we have examined
the hypothesis that CRP might play a role in modulating
angiogenesis, and as such, its presence in vascular regions
of developing arterial plaques may be implicated in their
progression to unstable, haemorrhagic lesions prone to
rupture. Our data shows that CRP, at concentrations com-
monly found in the circulation of patients with active
carotid disease, is highly pro-angiogenic both in vitro, and
in vivo. Furthermore, CRP activates cell signalling and
increases expression of key genes associated with angio-
genesis.
In order to show that the effects of CRP were due to CRP
itself and not other components, we have attempted to
address the controversy surrounding the influence of
¨contaminants¨ present in commercial preparations of
CRP. Notably, Pepys et al. demonstrated that pure natural
human CRP free from endotoxins and azide, was not pro-
inflammatory to macrophages in vitro [42]. More specifi-
cally, inhibition of HUVEC cell proliferation, eNOS gene
expression and increased apoptosis measured by activa-
tion of caspase-3/9, have been attributed to the presence
of azide in CRP preparations. Similarly, contaminating
LPS was shown to increase IL-8, ICAM-1 and MCP-1 gene
expression [39,40]. It is worthy of note, however, that the
effects of azide were demonstrated at concentrations
(0.0025%) equal to those produced by administration of
50 μg/ml CRP. In our study, concentrations of CRP and
therefore azide used in the majority of experiments were
much lower and in fact, had no significant effects on cell
growth and gene expression as demonstrated in the Taq-
Man microarrays. Even so, this highlights the importance
of using satisfactory controls when conducting this type of
assays. In our studies, all of the controls, used for compar-
ison with CRP tests, contained equivalent amounts of
azide so that direct comparisons were able to be made.
Finally, in our study, we show that the treatment of CRP
with detoxi-gel columns did not negate the pro-ang-
CRP stimulated BAEC proliferationFigure 2
CRP stimulated BAEC proliferation. The effect of 1–5 μg/ml 
CRP (non-detoxified and detoxified CRP [CRPdt]) for 72 h 
on BAEC proliferation is shown. Experiments were repeated 
at least twice in triplicate wells. * and ** indicate a statistically 
significant difference compared with the control cells (p > 
0.05 and 0.001 respectively).
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BMC Cell Biology 2008, 9:47 http://www.biomedcentral.com/1471-2121/9/47iogenic effects of CRP. Interestingly, assays performed
using purified LPS at concentrations that were similar to
or exceeded those reported in high purity human recom-
binant CRP from our commercial supplier [43,44] dem-
onstrated no significant effects on BAEC or HCAEC
angiogenesis or IL-8 gene activation. This is in agreement
with the recent findings of Dasu et al. who showed that
purified CRP was able to activate IL-8, IL-6, IL-1β, PAI-1
and eNOS in Toll-like receptor 4 knockout HAEC, indicat-
ing that the effects were not due to LPS contamination
[43].
In this study, we showed that CRP induces angiogenesis in
vitro in two separate sources of primary cultured vascular
EC as well as in vivo as judged by an increase in capillary
formation in the CAM assay, aortic ring assay and 3D-
Matrigel. The angiogenic potency of CRPdt was quite
strong, being 50–75% of that demonstrated by our posi-
tive control FGF-2 (25 ng/ml; comparisons not included).
One other study showed previously that CRP induced
proliferation of rabbit thoracic EC with a concomitant
increase in expression of p-ERK1/2, similar to our own
findings [44]. In their study, they controlled for LPS by
CRP induced tube-like structure formation in HCAECFigure 3
CRP induced tube-like structure formation in HCAEC. A, Representative images from control cells and cells treated with 1 ng/
ml LPS or 1 μg/ml of detoxified CRP [CRPdt] for 24 h are shown. B, Bar graph showing tube length as a percentage of control. 
Experiments were performed at least twice by triplicate. ** indicates a statistically significant difference compared with the 
control (p < 0.001).
A
Control LPS
CRPdt
B
Control CRP
1 Pg/ml
CRP
5 Pg/ml
CRPdt
5 Pg/ml
CRPdt
1 Pg/ml
LPS
1 ng/ml
Tu
be
le
n
gt
h
(%
 of
co
n
tr
ol
)
0
100
200
300
400
500
600
**
**
**
**
CRPdtPage 5 of 14
(page number not for citation purposes)
BMC Cell Biology 2008, 9:47 http://www.biomedcentral.com/1471-2121/9/47
Page 6 of 14
(page number not for citation purposes)
CRP induced tube-like structure formation in BAECFigure 4
CRP induced tube-like structure formation in BAEC. Representative images from control cells and cells treated with 1 ng/ml 
LPS, FGF-2 (25 ng/ml), 1 μg/ml of detoxified CRP [CRPdt] or CRP + blocking antibody against CRP for 24 h are shown.
Ͳ Ͳ
BMC Cell Biology 2008, 9:47 http://www.biomedcentral.com/1471-2121/9/47measuring levels with the Limulus assay which were
recorded as < 0.125 EU/ml. The authors, however, found
that increased proliferation occurred only at significantly
high CRP concentrations of (> 20 μg/ml), and further-
more, they did not consider the effects of azide. In agree-
ment with our findings, Bello et al (2008), showed that
CRP increases VEGF-A expression via PI3-kinase and
ERK1/2 pathway and thus could play a role in the angio-
genesis process [45]. Orozlan et al. found no effects of
CRP on HUVEC proliferation although they did not sup-
ply data indicating the concentration of CRP used [46]. In
our previous studies where we have characterised various
types of vascular cells, we have found HUVEC to be the
least responsive to pro-angiogenic stimuli including
VEGF, FGF-2 and oligosaccharides of hyaluronan; there-
fore, these results are perhaps not surprising [41]. The fact
CRP induced tube-like structure formation in BAECFigure 5
CRP induced tube-like structure formation in BAEC. A, Bar 
graph showing tube length as a percentage of control. Exper-
iments were performed at least twice by triplicate. B, Bar 
graphs showing tube length as a percentage of control from 
cells treated with FGF-2 (25 ng/ml), 1 μg/ml of detoxified 
CRP [CRPdt] or CRP + blocking antibody against CRP for 24 
h. * and ** indicate a statistically significant difference com-
pared with the control cells (p > 0.05 and 0.001 respectively.
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CRP stimulated spoke wheel blood vessel formation in the AM assayFigure 6
CRP stimulated spoke wheel blood vessel formation in the 
CAM assay. A, Negative control (score 0.5); B, CRPdt-
treated (5 μg/ml; score 2.0); C, Positive control, FGF-2-
treated (100 ng/ml) (score 3.0). Spoke wheel patterns can be 
seen in both CRP- and FGF-2-treated samples originating 
from the pellet (designated by dotted circles). Experiments 
were performed twice. A representative example of 5 CAM's 
used per experiment is shown.
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BMC Cell Biology 2008, 9:47 http://www.biomedcentral.com/1471-2121/9/47that CRP did not stimulate HCAEC proliferation suggests
that there may be variability in cellular responses depend-
ent on cell type, and EC have been shown in many studies
to be heterogeneous in this regard. Indeed, in contrast to
our results, one recent study showed induction of apopto-
sis in human umbilical EC (HUVEC) incubated with CRP,
analyzed by TUNEL and caspase-3 activity assay and inhi-
bition [47]. However, the above study used 10 μg/ml of
CRP in their assay and we observed a pro-angiogenic effect
of CRP at 1 and 5 μg/ml. Moreover, the apoptotic effect of
CRP was demonstrated in HUVEC and cellular response
may be dependent on EC origin. In addition, in the same
study the authors showed that CRP treatment of mono-
cluclear cells induced production of MMP-9 which is
involved in extraclellular matrix degradation, cell migra-
tion and release of angiogenic factors necessary to elicit
angiogesis [48,49] Verma et al. showed that purified CRP
attenuated NO release in human saphenous vein EC,
increased apoptosis and inhibited capillary-like tube for-
mation in matrigel at 5–25 μg/ml [32]; however, they did
not control for the effects of azide. The same authors also
demonstrated that CRP inhibited EC progenitor differen-
tiation, survival and function through a process involving
a reduction in NO expression appeared to be carried out
without the use of suitable azide and endotoxin controls
[50].
Our data showing a potent angiogenic effect of CRP/
CRPdt is strongly backed up by the results of our real-time
TaqMan PCR microarrays. Using our specifically designed
targeted microfluidity cards, we showed up-regulation of
key genes involved in promotion of vascularisation. We
found 6 genes up-regulated by CRPdt on HCAEC between
12–72 h. VEGF receptor-2 (KDR), the main receptor
mediating both signal transduction and the biologic
responses, including angiogenesis, triggered by VEGF in
endothelial cells [51], was significantly induced by CRPdt.
Up-regulation of this receptor together with growth fac-
tors such as PDGF- B involved in cell proliferation and
angiogenesis [52], could be one mechanism through
Aortic ring assayFigure 7
Aortic ring assay. A, control. B, Incubated with FGF-2 (25 ng/ml). C, Incubated with 1 μg/ml of detoxified CRP [CRPdt]. D, Bar 
graphs showing area covered by vascular sprouts in control, FGF-2 (25 ng/ml) and CRPdt (1 μg/ml).
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BMC Cell Biology 2008, 9:47 http://www.biomedcentral.com/1471-2121/9/47which CRP initiates its angiogenic effects. Notch1 was
increased after 12 h of CRP treatment. Notch1 is required
for formation of correct sprouting and branching patterns
during VEGF-stimulated angiogenesis in vivo [53].
Recently, cyclic strain was shown to up-regulate Notch1 in
human vascular EC and this process was responsible for
significantly increased tube-formation in matrigel sug-
gesting a role in development of atherosclerosis [54].
Notch3 is other member of the Notch family that seems
to be critical for vascular cell survival and is required for
the arterial identity and maturation of vascular cells
[55,56]. One particularly novel finding was the up-regula-
tion of CYR61. CYR61 is an extracellular matrix-associ-
ated protein expressed within developing vasculature,
which promotes angiogenesis both in vitro and in vivo
[57]. CYR61 binds directly to the integrin αvβ3 present on
activated EC and mediates chemotaxis and tube forma-
tion. Finally, ID1, originally identify as a dominant-nega-
tive antagonist of the basis helix-loop-helix (HLH)
transcription factors has been recently involved in VEGF-
induced angiogenesis in human endothelial cells [58].
Future work should be addressed to determine the expres-
sion, localization and relevance of these proteins in ang-
iogenic regions of developing complicated atherosclerotic
lesions.
This discussion would not be complete without a brief
mention of the recently characterised modified CRP
(mCRP). Evidence has emerged that native pentametric
CRP can change its structural conformation following sep-
aration into monomers. Following re-arrangement, for-
mation of the mCRP sub-unit has increased binding
affinity for plasma membranes, and has been shown to be
preferentially expressed in tissues [59]. Recent evidence
suggest that mCRP may be a significantly weaker stimula-
tor of pro-inflammatory molecules in vascular EC (e.g. IL-
8, PAI-1 and prostaglandin F1-α), and hence atherogenic
effects [60]. However, it is important to remember that
3D-matrigel invasion assay in control, FGF-2 (25 ng/ml)(arrows) and CRPdt (1 μg/ml)(arrows)Figure 8
3D-matrigel invasion assay in control, FGF-2 (25 ng/ml)(arrows) and CRPdt (1 μg/ml)(arrows). Dotted line marks the interface 
between the first and the second layer of the matrigel.
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BMC Cell Biology 2008, 9:47 http://www.biomedcentral.com/1471-2121/9/47native CRP can be found at high concentration in many
hospital patients and most of them do not develop acute
cardiovascular events. This suggests that cardiovascular
effects of CRP if indeed important maybe due to its mod-
ified form.
Conclusion
Our findings strongly suggest an important role for CRP in
modulation of angiogenesis and as such, CRP could pro-
mote the formation of intimal neovessels of complicated
unstable plaques increasing the likelihood of rupture. The
distribution of both native and mCRP should be investi-
gated in complicated atherosclerotic plaques and further
studies should aim to identify the mechanisms of cell
binding and intracellular mechanisms leading to cellular
activation.
Methods
Materials
Human coronary artery EC (HCAEC), EC basal medium
and growth factor supplements were bought from TCS
CellWorks (Botolph Claydon, UK). HCAEC were used
between passage 2 and 6, and cultured according to the
manufacturer's instructions. Bovine aortic EC (BAEC)
were isolated from bovine arteries, seeded in DMEM (Inv-
itrogen) supplemented with 15% foetal calf serum, con-
taining penicillin and 100 μg/ml streptomycin (Sigma-
Aldrich, St Louis, MO) routinely cultured as described
elsewhere, and used between passage 3 and 6.41 Human
recombinant CRP was obtained from Calbiochem (San
Diego, California, USA). Sodium azide, phenylmethylsul-
fonyl fluoride (PMSF), leupeptin and lipopolysaccharide
(LPS; 20,000 endotoxin units (EU)/mg LPS) were pur-
chased from Sigma-Aldrich. Growth factor-reduced
Matrigel was bought from Beckton Dickinson (BD Bio-
sciences, San Jose, CA) and recombinant basic fibroblast
growth factor (FGF-2) was from R&D systems (Minneap-
olis, MN). Antibody to CRP was purchased from Sigma.
Experimental research carried on animals followed inter-
nationally recognized guidelines and was approved by
local ethical committe at Centro de Investigación Cardio-
vascular, CSIC-ICCC, Hospital de la Santa Creu i Sant Pau,
Barcelona, Spain.
CRP purity testing and endotoxin removal
CRP purity was checked by SDS-PAGE followed by
Coomassie blue staining where CRP was identified as a
single band [57]. Endotoxin concentrations in CRP sam-
CRP activated ERK1/2 in HCAECFigure 9
CRP activated ERK1/2 in HCAEC. A, Western blot showing 
the effect of 1–5 μg/ml CRP (non-detoxified and detoxified 
CRP [CRPdt]) on phosphorylation of ERK1/2 (pERK1/2) in 
HCAEC. The increase was similar to that produced by FGF-2 
(25 ng/ml). Total ERK1/2 protein levels were used as a load-
ing control. Experiments were performed at least twice and a 
representative example is shown. B, quantitative densito-
metic analysis of the blot shown in A. (ERK-1 [black bars]; 
ERK-2 [shaded bars]).
44 kDa
42 kDa
44 kDa
42 kDa
pERK1
pERK2
ERK1
ERK2
A
Control
CRP
1 Pg/ml
CRP
5 Pg/ml
CRPdt
5 Pg/ml
CRPdt
1 Pg/ml
FGF-2
25 ng/ml
B
0
1
2
3
4
5
6
7
R
el
at
iv
e
pE
R
K
Control CRP
1 Pg/ml
CRP
5 Pg/ml
CRPdt
5 Pg/ml
CRPdt
1 Pg/ml
FGF-2
25 ng/ml
Table 1: Angiogenesis-related genes modulated by CRP in HCAEC
Gene name Fold-increase (time)
Experiment #1
Fold-increase (time)
Experiment #2
Gene function
KDR/Flk-1/VEGFR2 1.53 (12 h) 1.94 (24 h) Cell survival, proliferation and angiogenesis44
PDGF-B 2.44 (24 h) 3.94 (12 h) Proliferation and angiogenesis45
Notch1 3.28 (12 h) 1.97 (12 h) Angiogenesis (spreading and branching)46
Notch3 2.03 (24 h) 4.46 (72 h) Vascular cell identity and survival47,48
CYR61/CCN1 4.94 (72 h) 3.91 (12 h) Connective tissue growth factor 49
ID1 2.65 (24 h) 1.94 (12 h) Cell cycle and angiogenesis50
PDGF, Platelet-derived growth factor; KDR: kinase-insert domain receptor; VEGFR2, vascular endothelial cell growth factor receptor-2; CYR61, 
Cysteine-rich angiogenic inducer 6; ID1, Inhibitor of DNA binding/differentiation-1.Page 10 of 14
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0.125 EU/ml, Chromogenix AB, Mölndal, Sweden). Puri-
fied LPS was included in control experiments at concen-
trations that exceeded those reported to be found in
human recombinant CRP from Calbiochem (1 ng/ml)
[58,59]. In all of the experiments CRP treated with detoxi-
gel columns (CRPdt) containing immobilized polymyxin
B was used to ensure the absence of pyrogens (Affinit-
yPak™ detoxi-Gel™ column; Pierce, Rockford, IL).
Removal of LPS was confirmed using the limulus assay.
Non-detoxified native CRP preparations were used for
comparison. To analyze the possible effect of sodium
azide present in the CRP preparations, cells were incu-
bated with 0.00005–0.0005% sodium azide, equivalent
to that found in 1–10 μg/ml CRP.
Response testing of HCAEC and BAEC to CRP: choice of 
CRP concentration
In this work, we investigated the effects of CRP at concen-
trations ranging from 1–10 μg/ml. Published data sug-
gests that normal circulating levels of CRP are < 1 μg/ml.
In pathological situations, such as in patients with inflam-
mation, and particularly in those with advanced unstable
atherosclerosis, CRP levels increase. CRP levels of < 1, 1 to
3, and > 3 μg/ml correspond to low-, moderate-, and high-
risk groups for future cardiovascular events [21].
Chemotaxis assay
BAEC or HCAEC were seeded at 7.3 × 104 cells/ml in 100
μl of serum poor medium on Transwell porous mem-
branes (Costar; 8-μm pore filter) plated into a 24-well
plate. Basal medium supplemented with 0.1% FBS and
CRP (1–5 μg/ml). We also incubed cells with CRP pre-
treated with antibody to CRP in order to confirm the effect
was due to CRP protein itself. FGF-2 (25 ng/ml) was used
as a positive control. For each experimental condition,
cells were treated in duplicate. After 24 h incubation, the
cells which did not migrate on the upper surface of the
membrane were removed with a cotton swab soaked with
PBS then wiped with a dried cotton swab. The cells which
had migrated were fixed with 4% paraformaldehyde, left
to air dry, stained with Giemsa and counted with an opti-
cal microscope. All experiments were performed at least
three times.
Effect of CRP on BAEC and HCAEC proliferation
BAEC were seeded in complete medium at a concentra-
tion of 2 × 104cells/ml (2 ml per well) in 6-well plates.
HCAEC were seeded in complete medium at a concentra-
tion of 2 × 104 cells/ml per well in 24-well plates. After
attachment (4 h) the medium was replaced with serum
poor medium (SPM), containing 2.5% FBS (BAEC) and
5% FBS (HCAEC) in which the cells grew at a significantly
reduced rate. CRP was added at concentrations ranging
from 1–5 μg/ml. After 72 h incubation, cells were washed
with PBS without Ca2+ and Mg2+, detached with trypsin
then counted using a Coulter counter (Coulter Electron-
ics, Hialeah, FL). All experiments were performed at least
three times.
Tube-like structure formation assay
BAEC or HCAEC (2 × 106 cells/ml) were cultured in com-
plete medium and mixed in an equal volume with 40 μl
of growth factor-reduced Matrigel (10 mg/ml) with or
without CRP at concentrations varying between 1 and 5
μg/ml. We also incubed cells with CRP pre-treated with
antibody to CRP in order to confirm the effect was due to
CRP protein itself. FGF-2 (25 ng/ml) was used as a posi-
tive control. Half of the mixture was allowed to polymer-
ise as three-dimensional droplets in 48-well plates and
each experimental condition was carried out in duplicate.
After polymerization (1 h), each spot of Matrigel was
bathed in 500 μl of complete medium for 24 h. The cells
were then fixed with 4% paraformaldehyde for 10 min.
the total length of tube-like structures was measured by
light microscopy after 48 h in a double-blinded fashion.
All experiments were performed at least three times.
Chick Chorioallantoic membrane (CAM) assay
The angiogenic activity of compounds was determined in
the chick chorioallantoic assay (CAM) as described previ-
ously [61]. CRPdt (5 μg) was applied to the membrane
(10 membranes per treatment) and the resultant angio-
genesis scored as 0, negative; 0.5, change in vessel archi-
tecture; 1, partial spoke wheel (1/3 of circumference
exhibits directional angiogenesis); 2, spoke wheel; 3 or
greater, strong and full spoke wheel. Control membranes
had the equivalent concentration of sodium azide added.
To photograph the membrane, 2 cm3 of a 50% emulsion
of aqueous paraffin oil containing 2% Tween-80 was
injected at the site of application and photographed using
a Leitz dissecting microscope. FGF-2 (100 ng) was used as
a positive control. All experiments were performed at least
three times. This approach enabled calculation of an accu-
mulated response in each group. All experiments were
performed at least five times and statistical differences
were determined by the Mann-Whitney U test and the
data is expressed as a median value (m).
Rat aortic ring sprouting assay
Aortic ring assays were performed as described with minor
modifications [62]. Aortas were removed from adult male
Wistar rats (250 g) and immediately placed in ice cold EC
growth medium (ECGM) supplemeted with 1% PBS.
After removing the fibro-adipose tissue, arteries were cut
into 1 mm long cross section, rinsed in PBS and placed on
the Matrigel-coated wells. Artery rings were covered with
addition layer of Matrigel (10 mg/ml) and incubated with
ECGM at 37°C in 5% CO2. After 24 hours incubation,
medium was replaced with medium ECGM with or with-Page 11 of 14
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tive. After 6 days, images of aortic rings were taken using
a Leica DMIRE microscope and the outgrowth area delin-
eated and measured. Sprouts was measuring using Image
software and analyzed by calculating the area occupied by
microvessel sprouts eminating from the arterial ring.
Invasion assay in a 3D-Matrigel™ matrix
To assess the effect of CRP on EC invasion into a second
Matrigel™ layer the first layer was formed in 0.1% FCS and
25 ng/ml of FGF-2 and tube-like structures allowed to
form over 24 h. Then a second layer of Matrigel™ was
formed around the first layer containing 1 μg/ml of CRP.
After polymerisation, these wells were incubated with 500
μl of medium containing 0.1% FCS with or without 1 μg/
ml CRP or with 25 ng/ml FGF-2 as a positive control for a
further 24 h. The wells were fixed with 4% PFA and the
number of invading cells was quantified by visualising the
border with the Matrigel™ using phase contrast micros-
copy and counting the number of cells in three different
areas of the second matrix layer. Experiments were per-
formed in triplicate wells.
RNA extraction, cDNA synthesis and TaqMan Low-
Density Array
Our pilot studies demonstrated up-regulation of IL-8,
(used as a marker of EC activation) by CRP [60], at con-
centrations ranging from 1–25 μg/ml. ECs (BAEC and
HCAEC) we incubated for 4–72 h in presence or absence
of CRP and IL-8 expression was assessed by real-Time
PCR. IL-8 expression was not abrogated by pre-incubation
with polymyxin B (5 μg/ml) used to exclude the potential
effect of traces of LPS potentially present in CRP prepara-
tions. RNA was isolated from semi-confluent cultured
HCAEC in SPM following treatment for 4–72 h with CRP
(5 μg/ml) or sodium azide alone using the RNeasy™ Mini
Kit (Qiagen) according to the manufacturer's instructions.
The TaqMan low-density array (Applied Biosystems) con-
sists of 48 selected TaqMan primers and probes (see Addi-
tional file 1) preconfigured in a 384-well format and
spotted on a microfluidic card (2 replicates per assay).
Control HCAEC and those treated with CRP for different
times (4 h, 12 h, 24 h and 72 h) were prepared in tripli-
cate, then the three wells were pooled together. 50 μl of
cDNA from each sample was loaded on the TaqMan Low-
Density Array as described [5]. Real-time RT-PCR amplifi-
cations were run on an ABI Prism® 7900 Ht sequence
Detection System (Applied Biosystems) with a TaqMan
Low-Density Array Upgrade. Thermal cycling conditions
were as follows: 2 min at 50°C; 10 min at 95°C; 40 cycles
of denaturation at 95°C for 15 seconds; and annealing
and extension at 60°C for 1 min. The experiment was per-
formed twice and only genes up-regulated in both experi-
ments were considered validated.
Western blotting
BAEC or HCAEC were seeded in complete medium in 24-
well plates. After 48 h incubation, the medium was
replaced with SPM for 48 h before addition of CRP (1–5
μg/ml) or 25 ng/ml FGF-2 for 8 min and western blotting
was carried out using standard process as previously
described [41]. Proteins were electroblotted (Hoefer,
Bucks, UK) onto nitrocellulose filters (1 h) and the filters
were blocked for 1 h at room temperature in TBS-Tween
(pH 7.4) containing 1% BSA. Filters were stained with the
following primary antibodies diluted in the appropriate
blocking buffer, overnight at 4°C on a rotating shaker:
rabbit monoclonal antibodies to ERK1/2 (1:1000) and
mouse monoclonal antibodies to phosphorylated ERK1/
2 (P-ERK1/2, 1:1000) from Santa Cruz Biotechnology.
After washing filters were stained with either goat anti-
rabbit or rabbit anti-mouse horse-radish peroxidase-con-
jugated secondary antibodies (1:1000, 1 h, room temper-
ature). Proteins were visualized using ECL
chemiluminescent detection. All experiments were per-
formed at least twice.
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